Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AssigneeGenentech, Inc.
InventorsCamellia Adams, Leonard Presta, Mark Sliwkowski
Life of this patent
Estimating the term…
Abstract
The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
Claims10
A method of treating ErbB2-expressing cancer in a human, comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2 and blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB-12697) to ErbB2, wherein the cancer overexpresses an ErbB ligand.
A method of treating ErbB2-expressing cancer in a human patient, comprising administering to the patient a therapeutically effective amount of a humanized version of monoclonal antibody 2C4 (ATCC HB-12697), wherein the patient produces a greater than normal level of ErbB ligand.
Dependencies are inferred from the claim text.